Trial Profile
A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Fluorouracil; Folic acid; Folinic acid
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- 26 Oct 2021 Results of a pooled analysis of integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients from the 4 clinical trials published in the British Journal of Cancer
- 18 Apr 2019 Status changed from active, no longer recruiting to completed.
- 22 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.